An Open, Prospective, Randomized Study Comparing the Immunogenicity and Safety of Two Inactivated Hepatitis A Pediatric Vaccines in Toddlers, Children and Adolescents in China

Pediatric Infectious Disease Journal

Volumn 32, Issue 2, 2013, Pages e77-e81

  Li, Rong Cheng ^a   Li, YanPing ^a   Yi, Nong ^a   Huang, Lirong ^a   Wan, Zongju ^a   Zhang, Yanping ^a   Rasuli, Anvar ^a  

^a Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control   (France)

Author keywords

Comparative study; Hepatitis A vaccines; Immunogenicity; Pediatric; Safety

Indexed keywords

HEPATITIS A VACCINE;

ADOLESCENT; ANOREXIA; ANTIBODY TITER; ARTICLE; BRONCHOPNEUMONIA; CHILD; CHILD HEALTH CARE; CHINA; CONTROLLED STUDY; CRYING; DROWSINESS; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FEVER; HEADACHE; HEPATITIS A VIRUS; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MALAISE; MALE; MYALGIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; TONSILLITIS; VACCINATION; VOMITING;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHINA; DRUG TOXICITY; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; MALE; PROSPECTIVE STUDIES; VACCINES, INACTIVATED;

EID: 84873023893     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318271c4c3     Document Type: Article

References (25)

1. Jeong SH, Lee HS. Hepatitis A: clinical manifestations and management. Intervirology. 2010;32:15-19
2. Mathur P, Arora NK. Epidemiological transition of hepatitis A in India: issues for vaccination in developing countries. Indian J Med Res. 2008;128:699-704
3. Barzaga BN. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine. 2000;18(suppl 1):S61-S64
4. World Health Organization. WHO position paper on hepatitis A vaccines-June 2012 Wkly Epidemiol Rec. 2012;87:261-276
5. Mohd Hanafiah K, Jacobsen KH, Wiersma ST. Challenges to mapping the health risk of hepatitis A virus infection. Int J Health Geogr. 2011;10:57
6. Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28:6653-6657
7. World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2011—conclusions and recommendations. Wkly Epidemiol Rev. 2012;87:1-16
8. Zhuang GH, Pan XJ, Wang XL. A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China. Vaccine. 2008;26:4608-4616
9. Fangcheng Z, Xuanyi W, Mingding C, et al. Era of vaccination heralds a decline in incidence of hepatitis A in high-risk groups in China. Hepat Mon. 2012;12:100-105
10. Heinricy U, Stierhof YD, Pfisterer M, et al. Properties of a hepatitis A virus candidate vaccine strain. J Gen Virol. 1987;68(pt 9):2487-2493
11. Vidor E, Fritzell B, Plotkin S. Clinical development of a new inactivated hepatitis A vaccine. Infection. 1996;24:447-458
12. Vidor E, Dumas R, Porteret V, et al. Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data. Eur J Clin Microbiol Infect Dis. 2004;23:300-309
13. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857-872
14. Orr N, Klement E, Gillis D, et al. Long-term immunity in young adults after a single dose of inactivated Hepatitis A vaccines. Vaccine. 2006;24:4328-4332
15. Abarca K, Ibánez I, Perret C, et al. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children. Int J Infect Dis. 2008;12:270-277
16. Soysal A, Gokçe I, Pehlivan T, et al. Interchangeability of a hepatitis A vaccine second dose: Avaxim 80 following a first dose of Vaqta 25 or Havrix 720 in children in Turkey. Eur J Pediatr. 2007;166:533-539
17. Ministerio de Salud de la Nación. Boletín Epidemiológico Anual 2010. Available at:http://msal.gov.ar/htm/site/sala_situacion/PANELES/bep-anual-2010/BEPANUAL_2010.pdf Accessed July 16, 2012.
18. Espul C, Benedetti L, Cuello H, et al. Persistence of immunity from one year of age after one or two doses of hepatitis A vaccine given to children in Argentina. Hepat Med. 2012;4:53-60
19. Mayorga Pérez O, Herzog C, Zellmeyer M, et al. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. J Infect Dis. 2003;188:671-677
20. Lolekha S, Pratuangtham S, Punpanich W, et al. Immunogenicity and safety of two doses of a paediatric hepatitis A vaccine in thai children: comparison of three vaccination schedules. J Trop Pediatr. 2003;49:333-339
21. López EL, Contrini MM, Xifró MC, et al. Hepatitis A vaccination of Argentinean infants: comparison of two vaccination schedules. Vaccine. 2007;25:102-108
22. Zuckerman JN, Kirkpatrick CT, Huang M. Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A. J Travel Med. 1998;5:18-22
23. Dagan R, Greenberg D, Weber F. Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up. Vaccine. 2005;23:5144-5148
24. López EL, Contrini MM, Mistchenko A, et al. Long-term immunity after two doses of inactivated hepatitis A vaccine, in Argentinean children. Pediatr Infect Dis J. 2010;29:568-570
25. Ott JJ, Irving G, Wiersma ST. Long-term protective effects of hepatitis A vaccines. A systematic review. Vaccine. 2012;31:3-11 Available at: http://dx.doi.org/10.1016/j.vaccine.2012.04.104. Accessed July 16, 2012.